POSEIDA THERAPEUTICS INC's ticker is PSTX and the CUSIP is 73730P108. A total of 69 filers reported holding POSEIDA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,482,975 | +35.2% | 1,043,267 | 0.0% | 1.02% | +13.8% |
| Q2 2023 | $1,836,150 | -42.9% | 1,043,267 | 0.0% | 0.90% | -41.8% |
| Q1 2023 | $3,213,262 | -41.9% | 1,043,267 | 0.0% | 1.55% | -57.6% |
| Q4 2022 | $5,529,315 | +50.1% | 1,043,267 | 0.0% | 3.65% | +49.2% |
| Q3 2022 | $3,683,000 | +36.8% | 1,043,267 | 0.0% | 2.45% | +27.3% |
| Q2 2022 | $2,692,000 | -42.4% | 1,043,267 | 0.0% | 1.92% | -23.8% |
| Q1 2022 | $4,674,000 | -34.2% | 1,043,267 | 0.0% | 2.52% | +0.6% |
| Q4 2021 | $7,105,000 | -6.6% | 1,043,267 | 0.0% | 2.51% | +65.3% |
| Q3 2021 | $7,605,000 | -27.3% | 1,043,267 | 0.0% | 1.52% | -9.4% |
| Q2 2021 | $10,454,000 | +4.9% | 1,043,267 | 0.0% | 1.67% | -6.6% |
| Q1 2021 | $9,963,000 | -12.9% | 1,043,267 | 0.0% | 1.79% | -8.8% |
| Q4 2020 | $11,445,000 | +23.7% | 1,043,267 | 0.0% | 1.96% | -33.5% |
| Q3 2020 | $9,254,000 | – | 1,043,267 | – | 2.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 3,567,985 | $8,491,804 | 2.58% |
| Aisling Capital Management LP | 1,043,267 | $2,482,975 | 1.02% |
| Atom Investors LP | 156,168 | $371,680 | 0.08% |
| Pentwater Capital Management LP | 5,975,000 | $14,220,500 | 0.08% |
| CORNERCAP INVESTMENT COUNSEL INC | 79,709 | $189,707 | 0.04% |
| Forefront Analytics, LLC | 24,969 | $59,428 | 0.03% |
| Callan Capital, LLC | 76,559 | $182,210 | 0.02% |
| XTX Topco Ltd | 40,782 | $97,061 | 0.02% |
| Advisory Services Network, LLC | 257,271 | $612,305 | 0.02% |
| RBF Capital, LLC | 70,171 | $167,007 | 0.01% |